Prognosis
Pfizer to Test Second Paxlovid Course in Patients With Covid Rebound
- CEO Bourla had suggested second course when rebound surfaced
- Biden, Fauci both experienced rebound after taking Covid drug
This article is for subscribers only.
Pfizer Inc. was ordered by US regulators to test the effects of an additional course of Paxlovid among people who experience a rebound in Covid-19 after treatment, putting the drug through further study as reports of the mysterious phenomenon continue to mount.
The company must produce initial results of a randomized controlled trial of a second course of the antiviral by Sept. 30, 2023, according to a letter from the regulator to Pfizer dated Aug. 5. The letter, which describes changes in Paxlovid’s emergency authorization, was confirmed by the Food and Drug Administration in an email.